http://rdf.ncbi.nlm.nih.gov/pubchem/patent/MX-PA05000723-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_05ff905fdc49089f5f25746eaeb40190 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-06 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-02 |
| filingDate | 2003-07-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1877f92d767adac5a42bbed42c644171 |
| publicationDate | 2005-04-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | MX-PA05000723-A |
| titleOfInvention | COMBINATION OF AN ALOSTERIC METALOPROTEINASA-13 MATRIX INHIBITOR WITH A SELECTIVE CYCLOOXYGENASE-2 INHIBITOR THAT IS NOT CELECOXIB OR VALDECOXIB. |
| abstract | The invention provides a combination, comprising an allosteric inhibitor of MMP-13, or a pharmaceutically acceptable salt thereof, and a selective COX-2 inhibitor, or a pharmaceutically acceptable salt thereof, which is not celecoxib or valdecoxib. This invention also provides a method for treating a disease that is sensitive to the inhibition of MMP-13 and cyclooxygenase-2, which comprises administering to a patient suffering from said disease the combination of the invention comprising an MMP-13 allosteric inhibitor, or a pharmaceutically acceptable salt thereof, and a selective COX-2 inhibitor, or a pharmaceutically acceptable salt thereof, which is not celecoxib or valdecoxib. This invention also provides a pharmaceutical composition, comprising the combination of the invention comprising an allosteric inhibitor of MMP-13, or a pharmaceutically acceptable salt thereof, with a selective COX-2 inhibitor, or a pharmaceutically acceptable salt thereof, which is not celecoxib or valdecoxib, and a pharmaceutically acceptable carrier, diluent or excipient. This invention also provides a combination comprising an MMP-13 allosteric inhibitor, or a pharmaceutically acceptable salt thereof, with an NSAID, or a pharmaceutically acceptable salt thereof. This invention also provides a method for treating a disease that is sensitive to the inhibition of MMP-13 and cyclooxygenase-2, which comprises administering to a patient suffering from such a disease the combination of the invention comprising an MMP-13 allosteric inhibitor, or a pharmaceutically acceptable salt thereof, with an NSAID, or a pharmaceutically acceptable salt thereof. The invention also provides a pharmaceutical composition, comprising the combination of the invention comprising an allosteric inhibitor of MMP-1 3, or a pharmaceutically acceptable salt thereof, with an NSAID, or a pharmaceutically acceptable salt thereof, and a vehicle, pharmaceutically acceptable diluent or excipient. The combinations of the invention can also be combined additionally with other pharmaceutical agents depending on the disease to be treated. |
| priorityDate | 2002-07-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 766.